Arrowhead Pharmaceuticals, Inc. announced that the Chinese National Medical Products Administration (NMPA) has approved Redemplo (plozasiran) for the reduction of triglyceride levels in adult patients with familial chylomicronemia… read more.
Knee injuries in rugby players occur with high incidence and severity, posing a significant burden on athletes. Although many studies on rugby injuries have been published, few combine… read more.
Flu infections are rising sharply across the United States, contributing to at least 81,000 hospitalizations and 3,100 deaths so far this season, according to the U. S. Centers for… read more.
Pelthos Therapeutics Inc. announced it has acquired Xeglyze (abametapir) from Hatchtech Pty Ltd., an Australian biotech company, for $1.8 million. Xeglyze is a pediculicide indicated for the topical… read more.
The study shows that this drug pair works far better together than either agent alone, offering a realistic and potentially fast path toward a new antifibrotic therapy. Liver… read more.
Researchers report that ending the use of glucagon-like peptide-1 (GLP-1) receptor agonists for weight loss is associated with weight regain and a reversal of heart health markers. The… read more.
Johnson & Johnson announced that the European Commission (EC) has extended the marketing authorisation for Tremfya (guselkumab) as a subcutaneous treatment to treat moderate to severe plaque psoriasis… read more.
China has achieved significant advancements in gastroenterology and digestive endoscopy, according to the 2024 national report published in the Chinese Medical Journal. Drawing data from the National Clinical Improvement… read more.
Analysis of 4.37 million patient records in England finds resources asymmetrically impacted by winter cold and summer heat, with about 64% linked to common cold days while very… read more.
The Ministry of Health, Labour and Welfare in Japan has granted marketing and manufacturing authorization for Dupixent (dupilumab) for the treatment of bronchial asthma in children aged 6… read more.
A team led by investigators at Mass General Brigham and Dana-Farber Cancer Institute has developed and validated an artificial intelligence (AI)–based noninvasive tool that can predict the likelihood that a… read more.
Patients who start their blood pressure treatment with ARB drugs continue with the same medicine to a greater extent than patients who start out with other drugs. Choosing… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
